BCYC - Why Shares of Bicycle Therapeutics Were Rising on Monday
2023-09-11 14:19:40 ET
Shares of Bicycle Therapeutics (NASDAQ: BCYC) were up 9% as of 1:30 p.m. ET on Monday after the healthcare stock climbed as high as 10.4% earlier in the day. The company's shares are still down more than 8% so far this year.
The clinical-stage biotech company focuses on short amino acid sequences that form stable loops called bicyclic peptides, or bicycles, to treat diseases that the company says are underserved by existing therapies. Many of the company's therapies are being looked at to treat solid tumors. These bicyclic peptides bind with molecules with high affinity and selection, making them good drug candidates for a variety of conditions.
On Monday, the company's shares rose when it said that, after discussions with the Food and Drug Administration (FDA), it is planning on a phase 2/3 investigational trial for BT8009 to treat metastatic bladder cancer. The trial is now expected to begin in the first quarter of 2024. The trial will have two cohorts; the first looks at the therapy in untreated bladder cancer and the second is for patients with previously treated bladder cancer.
For further details see:
Why Shares of Bicycle Therapeutics Were Rising on Monday